Myovant Sciences has submitted an NDA to the FDA for its once-daily relugolix for the treatment of women with heavy menstrual bleeding associated with uterine fibroids.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest